"They save human lives, they allow economies to reopen, but we sell them at the price of a meal", he said in the interview with Les Echos in France, Germany's Handelsblatt, Italy's Corriere Della Sera and El Mundo in Spain.
He said that recipients of the vaccine may also need to be injected every year to curb the spread of the virus, reported Harian Metro.
Residents who received their shots at the state vaccination megasite at the Meadowlands on Friday said they have no problem with a third shot, while others said they figured out that a third dose would be needed.
The government has ordered 40 million doses of the Valneva jab for 2022, "should we need to revaccinate any of the United Kingdom population", its vaccine task force said earlier this year.
Health officials have previously raised the possibility that the public may need booster COVID-19 shots.
According to Pfizer, its vaccine is more than 91 percent effective at protecting against COVID-19, and maintains that effectiveness for more than six months, similar to Moderna.
"Protection goes down by time", Bourla said, "but still [after] six months it is extremely, extremely high".
"It is extremely important to suppress the pool of people that can be susceptible to the virus", he said.
The head of the US-based company defended the cost of the jabs, which he said are saving lives and can help countries emerge from the pandemic.
A Northewell Health nurse inoculates a sheet metal worker with the first dose of the Pfizer vaccine. It seems strong but there is some waning of that and no doubt the variants challenge. they make these vaccines work harder.
"I think for planning purposes, planning purposes only, I think we should expect that we may have to boost".
In February, the company began testing whether a third shot could offer greater protection against emerging strains of the virus, like the concerning strain first detected in South Africa.
But beyond the study of 12,000 vaccinated people, exactly how long immunity lasts with two doses "remains to be seen", Dr Bourla said.
And Bourla said Thursday the company was working on a new formula that would allow the vaccine to be stored for four to six months at a normal temperature, rather than the minus 70 degrees Celsius (minus 94 Fahrenheit) or below now required.